Haoyang Peng
Dados Biográficos
| ID | 9999437 |
|---|---|
| NOME | Haoyang Peng |
| PRENOMES | Haoyang |
| SOBRENOME | Peng |
| ASSINATURA | PENG H |
| AFILIAÇÕES | Hebei Medical University |
| VERIFICADO | Não |
| TOTAL DE OBRAS | 1 |
| TOTAL DE CITAÇÕES | 0 |
| OBRAS COMO AUTOR | 1 |
| OBRAS COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2026 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2026 |
| ÍNDICE H | 0 |
Cost–utility and price threshold analysis of sacituzumab tirumotecan versus single-agent chemotherapy for previously treated metastatic triple-negative breast cancer in China
Background: Sacituzumab tirumotecan (Sac-TMT) has demonstrated survival benefits over chemotherapy in patients with previously treated metastatic triple-negative breast cancer (mTNBC). However, its economic value under different payment contexts in China remains uncertain. Methods: A state-transition (Markov) model was used to estimate lifetime costs and quality-adjusted life-years (QALYs) for Sac-TMT versus single-agent chemotherapy in second-li…
Sem obras proeminentes nesta página.
Cost–utility and price threshold analysis of sacituzumab tirumotecan versus single-agent chemotherapy for previously treated metastatic triple-negative breast cancer in China
Background: Sacituzumab tirumotecan (Sac-TMT) has demonstrated survival benefits over chemotherapy in patients with previously treated metastatic triple-negative breast cancer (mTNBC). However, its economic value under different payment contexts in China remains uncertain. Methods: A state-transition (Markov) model was used to estimate lifetime costs and quality-adjusted life-years (QALYs) for Sac-TMT versus single-agent chemotherapy in second-li…
Advanced Breast Cancer Therapies (1 obra) · Breast cancer (1 obra) · Breast Cancer Treatment Studies (1 obra) · Cancer Treatment and Pharmacology (1 obra) · China (1 obra) · List price (1 obra) · Metastatic breast cancer (1 obra) · Payment (1 obra) · Reimbursement (1 obra) · Willingness to pay (1 obra)